Biomarkers in the Endometrial Fluid, Tissue, and Follicular Fluid of Moderate/Severe Endometriosis Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Endometrial fluid, Endometrial biopsy, Follicular fluid.
- Who it may be relevant to
- Registry conditions: Endometriosis. Basic parameters: 18 years — 40 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Exploratory Study of Biomarkers in the Endometrial Fluid, Tissue, and Follicular Fluid of Moderate/Severe Endometriosis Patients: a Prospective Study
Overview
This study aims to explore biomarkers in the endometrial fluid and tissue of women with moderate to severe endometriosis, with a specific focus on those involved in pre-receptive endometrium and embryo implantation. This research has the potential to uncover diagnostic indicators of impaired pre-receptive endometrium, examine pathophysiological pathways, and identify future targets for therapeutic intervention. Ultimately, the findings may contribute to more personalized fertility treatments, offering new hope for women struggling with endometriosis-related infertility.
Interventions
- Diagnostic test Endometrial fluid
Endometrial fluid collection in the day of OPU - Diagnostic test Endometrial biopsy
Endometrial biopsy on the OPU day, Pipelle - Diagnostic test Follicular fluid
Follicular fluid sampling on the OPU day
Primary outcome measures
- Relative expression levels (e.g., fold change, normalized intensity, or concentration in pg/mL/ng/mL depending on biomarker assay) [Time frame: 2 years]
- Percentage of blastoids successfully implanted in vitro (% implantation rate) [Time frame: 2 years]
Secondary outcome measures (1)
- Relative expression levels (e.g., concentration in pg/mL, ng/mL, or fold change depending on assay) [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Age 18-40 years old
- Diagnosed with moderate/severe endometriosis by ultrasound or laparoscopy (patient group)
- Regular menstrual cycles 28-35 days
- Speak English or Swedish and agree to participate in the study
Exclusion criteria
- Pregnancy or lactation in the last 3 months
- Uterine anomalies
- Pelvic inflammatory disease, endometritis, STD
- Gynaecological cancers or other malignancies in the patient's history
- Smoking (more than 10 cigarettes per day) or alcohol abuse
- Immunosuppressing medicines
- Major abdominal or pelvic surgery in the last 3 months
- A specific genetic disease that is diagnosed before PGT in women undergoing treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Sweden · 1 center
- Karolinska Institute and Karolinska University Hospital Huddinge — Stockholm
Identifiers
NCT: NCT07182643 · 2025-03224-01